본문 바로가기
  • Home

A Case Report on the Improvement of Seborrheic Dermatitis Using Ortho-Cellular Nutrition Therapy (OCNT)

  • CELLMED
  • Abbr : CellMed
  • 2025, 15(5), pp.1~1
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : April 28, 2025
  • Accepted : April 30, 2025
  • Published : April 30, 2025

Jong-Bin Jo 1

1화순종로약국

Irregular Papers

ABSTRACT

Objective: Seborrheic dermatitis is a chronic inflammatory disorder that occurs on the scalp, face, ears, chest, and other areas of the body. The symptoms of this condition include excessive sebum production, erythema, scaling, and pruritus, and when it affects the scalp, it can present in a form resembling dandruff. This condition occurs in 1-3% of healthy adults and is more commonly observed in men, adolescents, young adults, and individuals of African descent. Currently, commonly used treatments include antifungal agents and anti-inflammatory medications. Steroids, immune-modulating drugs, mud therapy, and phototherapy are also used for treatment. Case Report: This case study was conducted on a Korean male in his twenties suffering from seborrheic dermatitis. The patient had struggled with acne-prone skin during his adolescence due to academic stress, which later progressed into seborrheic dermatitis. Therefore, Ortho-Cellular Nutrition Therapy (OCNT) was implemented to address his condition, prescribing anthocyanins, linoleic acid, bamboo leaves, rock salt, and salicylic acid to improve the associated symptoms. Conclusion: The patient reported improvement in the symptoms of seborrheic dermatitis after 8 months of OCNT. This case study is based on the health condition of a single patient, and it may not be universally applicable to all seborrheic dermatitis patients. However, the results were considered meaningful as the patient's quality of life significantly improved after undergoing the OCNT regimen.

Citation status

* References for papers published after 2023 are currently being built.